Tim Boreham
Author Profile
Stories by Tim Boreham
Health Check: For ASX biotechs, the business of America remains business
Health Kick Podcast: Neurizon’s ALS push and trial plans
Health Check: POTUS puts drug tariffs back on agenda… another case of TACO?
Health Check: Dental supplier faces the hard tooth that amalgam fillings are on the way out
Health Kick Podcast: Filamon’s bold push against cancer and chronic disease
Dr Boreham’s Crucible: ASX newbie Tetratherix plays it slow and steady
Health Check: Amid headwinds, Nanosonics goes bells and whistles on core device
Criterion: Buy, hold or sell CBA? Investors face their NFY resolution
Health Check: Promedicus shares smash record $300 barrier on back of mega deals
Health Check: Like bloodthirsty sharks, offshore acquirers are circling cheap biotech assets
Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected
Health Check: And the EOFY biotech winner is … gasp … a pot stock
Dr Boreham’s Crucible: ‘Better not louder’, Audeara is tuned in to the global audiology market
